×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Sarabjit Kour Nangra
Sarabjit Kour Nangra
Ads
DRL Q2 in line with view, coming qtrs may not be great: experts
Crack The Code: Decoding pharma sector
No disturbing trend in Dr Reddy's numbers except topline: Expert
Energy vertical pickup critical for Wipro to regain growth: Pros
Wipro Q4 in line; Q1FY17 guidance disappointing: Analysts
TCS Q4 margins disappoint but FY17 outlook good: Analysts
USFDA scans Cipla's Indore plant over norms violations
Wipro up 2%, aims to buy strategic design firm in Denmark
Tech Mahindra gains 2% on tie up with BPM software vendor
Infosys gains on hopes of meeting NASSCOM FY16 guidance
Ranbaxy effect playing on Sun Pharma's margins: Pros
Infosys dives 6% post poor Q4 results; TCS gains 2%
IPCA Labs tanks 9%, gets USFDA import alert for Ratlam unit
Halol contributes 35-40% to Sun's US sales: Angel Broking
Ranbaxy shares surge nearly 6% as Q4 net loss narrows
GSK Pharma a long term bet: Experts
Mohali import alert huge setback for Ranbaxy: Angel Broking
Lupin hit by drug pricing; biz did well globally: Angel
Two pharma stocks that can improve health of your portfolio
RBI's rupee move won't impact pharma companies, say experts
Post Q1, which stocks hit & missed in the pharma sector
Buy Cadila Healthcare on dips: Angel Broking
Angel Broking neutral on Sun Pharma
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio